Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Spiral Therapeutics

Request full access

Pharmaceutical company developing products for prevention of hearing loss and other inner ear disorders

South San Francisco, United StatesFounded 2016Biotech & Life Sciences

About Spiral Therapeutics

Spiral Therapeutics, founded in 2016, is a clinical-stage pharmaceutical company dedicated to developing treatments for inner ear disorders, a market with significant unmet needs affecting millions globally. The company was established by Hugo Peris, Justin S. Hanes, and Eugene de Juan. Peris, the CEO, comes from a family with a background in the pharmaceutical industry and holds a Master's in Health Economics and Pharmacoeconomics. Co-founder Justin S. Hanes is an accomplished researcher in nanomedicine and drug delivery, holding professorships at Johns Hopkins University and having co-founded several other biopharmaceutical companies.

The company's core focus is on overcoming the primary challenge of delivering drugs effectively to the inner ear. To address this, Spiral developed the Minimally Invasive Cochlear System (MICS™), a proprietary drug delivery platform. This platform is engineered for the precise, minimally invasive, and long-lasting administration of therapeutic agents directly to the cochlea, allowing for sustained release over weeks or months. The business model centers on advancing its therapeutic pipeline through clinical trials to gain regulatory approval and commercialize its treatments. The company secures funding through venture capital financing, having raised over $24 million from investors such as Catalio Capital Management, Savoir Capital, and Camden Partners to fund its research and development.

Spiral's lead product candidate is SPT-2101, a sustained-release steroid formulation of dexamethasone designed to treat Ménière's disease—a condition causing vertigo, tinnitus, and hearing loss. A key differentiator of SPT-2101 is its application via the MICS™ platform, which ensures the drug is delivered precisely to the round window membrane for extended release. Clinical trials have demonstrated promising results, showing SPT-2101 to be safe and effective in reducing the frequency and severity of vertigo episodes in patients. In 2023, the company strengthened its pipeline by acquiring assets from Otonomy, including data and rights related to other inner ear disorder treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
77.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Apr 2026 $27M $108M Ferring Ventures · Advanced Bionics · Uni-Bio Sciences · Gund Investment ↗
EARLY VC✓Equity / VC Aug 2023 — — Esperante Ventures · Ferring Ventures ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Spiral Therapeutics website traffic

Latest recorded traffic for Spiral Therapeutics is 1.1K monthly website visits, up 32.5% over the last three months. Spiral Therapeutics's team grew 10% over the past year.

Latest monthly visits1.1K 3-month web change+32.5% 1-year team growth+10%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Spiral Therapeutics in the South San Francisco ecosystem

Live from Dealroom

The Spiral Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • Camden Partners
  • Savoir Capital
  • Catalio Capital Management
  • Inveready
  • Sunghwan Choi
  • Humboldt Fund
  • Esperante Ventures
  • Ferring Ventures
  • Gund Investment
  • Advanced Bionics
  • Uni-Bio Sciences

Other known investors3 additional known investors

  • Johns Hopkins University
  • Patrick Aisher
  • StartX
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States88.9%
🇦🇺 Australia11.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Spiral Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Spiral Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.